AllianThera Partners with Insilico for Novel Cancer/Autoimmune Targets
March 25, 2021 at 05:47 AM EDT
AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. AllianThera said it intends to focus on disease biology, adopting novel technologies to address new targets, including targets that most biopharmas consider too risky to explore. Insilico Medicine combines AI, genomics, big data analysis and deep learning for in silico drug discovery. More details.... Share this with colleagues: // //
